Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Accumulated Expenses (2022 - 2025)

Historic Accumulated Expenses for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $11.1 million.

  • Century Therapeutics' Accumulated Expenses fell 1779.98% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year decrease of 1779.98%. This contributed to the annual value of $17.5 million for FY2024, which is 7204.65% up from last year.
  • According to the latest figures from Q3 2025, Century Therapeutics' Accumulated Expenses is $11.1 million, which was down 1779.98% from $11.7 million recorded in Q2 2025.
  • Century Therapeutics' 5-year Accumulated Expenses high stood at $17.5 million for Q4 2024, and its period low was $4.8 million during Q1 2022.
  • Over the past 4 years, Century Therapeutics' median Accumulated Expenses value was $9.9 million (recorded in 2023), while the average stood at $9.9 million.
  • As far as peak fluctuations go, Century Therapeutics' Accumulated Expenses soared by 7204.65% in 2024, and later crashed by 1779.98% in 2025.
  • Century Therapeutics' Accumulated Expenses (Quarter) stood at $9.8 million in 2022, then grew by 3.13% to $10.1 million in 2023, then soared by 72.05% to $17.5 million in 2024, then plummeted by 36.71% to $11.1 million in 2025.
  • Its Accumulated Expenses was $11.1 million in Q3 2025, compared to $11.7 million in Q2 2025 and $10.9 million in Q1 2025.